The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Links

 

Gene Review

DPYD  -  dihydropyrimidine dehydrogenase

Homo sapiens

 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of DPYD

 

Psychiatry related information on DPYD

 

High impact information on DPYD

 

Chemical compound and disease context of DPYD

 

Biological context of DPYD

 

Anatomical context of DPYD

 

Associations of DPYD with chemical compounds

 

Regulatory relationships of DPYD

  • Only five tumors failed to express TP but four of these expressed DPD, suggesting capecitabine resistance [26].
  • However, DPD was frequently co-expressed with AFP in poorly differentiated medullary areas of the AFP-positive gastric cancers [30].
  • The highly significant correlation of DPD mRNA with Per1 mRNA expression suggests control of DPD transcription by the endogenous cellular clock, which is more pronounced in women [31].
 

Other interactions of DPYD

 

Analytical, diagnostic and therapeutic context of DPYD

References

  1. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Bosch, T.M., Meijerman, I., Beijnen, J.H., Schellens, J.H. Clinical pharmacokinetics. (2006) [Pubmed]
  2. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Kornmann, M., Schwabe, W., Sander, S., Kron, M., Sträter, J., Polat, S., Kettner, E., Weiser, H.F., Baumann, W., Schramm, H., Häusler, P., Ott, K., Behnke, D., Staib, L., Beger, H.G., Link, K.H. Clin. Cancer Res. (2003) [Pubmed]
  3. 5-fluorouracil-related gene expression levels in primary colorectal cancer and corresponding liver metastasis. Kuramochi, H., Hayashi, K., Uchida, K., Miyakura, S., Shimizu, D., Vallbohmer, D., Park, S., Danenberg, K.D., Takasaki, K., Danenberg, P.V. Int. J. Cancer (2006) [Pubmed]
  4. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer. Ichikawa, W., Takahashi, T., Suto, K., Yamashita, T., Nihei, Z., Shirota, Y., Shimizu, M., Sasaki, Y., Hirayama, R. Br. J. Cancer (2004) [Pubmed]
  5. Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy. Jakob, C., Liersch, T., Meyer, W., Baretton, G.B., Häusler, P., Schwabe, W., Becker, H., Aust, D.E. Am. J. Surg. Pathol. (2005) [Pubmed]
  6. Alexithymia, depression, and treatment outcome in bulimia nervosa. de Groot, J.M., Rodin, G., Olmsted, M.P. Comprehensive psychiatry. (1995) [Pubmed]
  7. Depressed mood and executive dysfunction in early Parkinson's disease. Uekermann, J., Daum, I., Peters, S., Wiebel, B., Przuntek, H., Müller, T. Acta neurologica Scandinavica. (2003) [Pubmed]
  8. The construct validity of depressive personality disorder. McDermut, W., Zimmerman, M., Chelminski, I. Journal of abnormal psychology. (2003) [Pubmed]
  9. Mapping of the hypokalaemic periodic paralysis (HypoPP) locus to chromosome 1q31-32 in three European families. Fontaine, B., Vale-Santos, J., Jurkat-Rott, K., Reboul, J., Plassart, E., Rime, C.S., Elbaz, A., Heine, R., Guimarães, J., Weissenbach, J. Nat. Genet. (1994) [Pubmed]
  10. Extracellular calcium sensitivity and voltage-dependent calcium channels in C cells. Raue, F., Scherübl, H. Endocr. Rev. (1995) [Pubmed]
  11. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. Wei, X., McLeod, H.L., McMurrough, J., Gonzalez, F.J., Fernandez-Salguero, P. J. Clin. Invest. (1996) [Pubmed]
  12. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Maitland, M.L., Vasisht, K., Ratain, M.J. Trends Pharmacol. Sci. (2006) [Pubmed]
  13. Progestin is an essential factor for the initiation of the meiosis in spermatogenetic cells of the eel. Miura, T., Higuchi, M., Ozaki, Y., Ohta, T., Miura, C. Proc. Natl. Acad. Sci. U.S.A. (2006) [Pubmed]
  14. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Ichikawa, W., Uetake, H., Shirota, Y., Yamada, H., Nishi, N., Nihei, Z., Sugihara, K., Hirayama, R. Clin. Cancer Res. (2003) [Pubmed]
  15. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Smorenburg, C.H., Peters, G.J., van Groeningen, C.J., Noordhuis, P., Smid, K., van Riel, A.M., Dercksen, W., Pinedo, H.M., Giaccone, G. Ann. Oncol. (2006) [Pubmed]
  16. The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Oguri, T., Achiwa, H., Bessho, Y., Muramatsu, H., Maeda, H., Niimi, T., Sato, S., Ueda, R. Lung Cancer (2005) [Pubmed]
  17. Intratumoral induction of thymidylate synthase mRNA by 5-FU in colorectal cancer patients: association with survival. Tanaka-Nozaki, M., Tajiri, T., Tanaka, N., Furukawa, K., Takasaki, H., Yoshimura, K., Suzuki, H., Naito, Z., Sugizaki, Y., Merk, H.F., Blömeke, B., Kato, S. Oncol. Rep. (2003) [Pubmed]
  18. Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer. Miyoshi, Y., Uemura, H., Ishiguro, H., Kitamura, H., Nomura, N., Danenberg, P.V., Kubota, Y. Prostate Cancer Prostatic Dis. (2005) [Pubmed]
  19. TYMS and DPYD polymorphisms in a Turkish population. Süzen, H.S., Yüce, N., Güvenç, G., Duydu, Y., Erke, T. Eur. J. Clin. Pharmacol. (2005) [Pubmed]
  20. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. Zhu, A.X., Puchalski, T.A., Stanton, V.P., Ryan, D.P., Clark, J.W., Nesbitt, S., Charlat, O., Kelly, P., Kreconus, E., Chabner, B.A., Supko, J.G. Clinical colorectal cancer. (2004) [Pubmed]
  21. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Beck, A., Etienne, M.C., Chéradame, S., Fischel, J.L., Formento, P., Renée, N., Milano, G. Eur. J. Cancer (1994) [Pubmed]
  22. Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen. Grem, J.L., Danenberg, K.D., Behan, K., Parr, A., Young, L., Danenberg, P.V., Nguyen, D., Drake, J., Monks, A., Allegra, C.J. Clin. Cancer Res. (2001) [Pubmed]
  23. Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. Ishikawa, Y., Kubota, T., Otani, Y., Watanabe, M., Teramoto, T., Kumai, K., Takechi, T., Okabe, H., Fukushima, M., Kitajima, M. Anticancer Res. (1999) [Pubmed]
  24. Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. Amatori, F., Di Paolo, A., Del Tacca, M., Fontanini, G., Vannozzi, F., Boldrini, L., Bocci, G., Lastella, M., Danesi, R. Pharmacogenet. Genomics (2006) [Pubmed]
  25. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in thymoma. Sasaki, H., Fukai, I., Kiriyama, M., Kaji, M., Yano, M., Yamakawa, Y., Fujii, Y. Surgery today. (2003) [Pubmed]
  26. Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults. Patel, A., Pluim, T., Helms, A., Bauer, A., Tuttle, R.M., Francis, G.L. Cancer Chemother. Pharmacol. (2004) [Pubmed]
  27. Prognostic significance of a combination of thymidylate synthase and dihydropyrimidine dehydrogenase activities in grades 1 and 2 superficial bladder cancer. Mizutani, Y., Wada, H., Yoshida, O., Fukushima, M., Bonavida, B., Kawauchi, A., Miki, T. Oncol. Rep. (2002) [Pubmed]
  28. Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. Miyazaki, K., Shibahara, T., Sato, D., Uchida, K., Suzuki, H., Matsui, H., Yanaka, A., Nakahara, A., Matsuzaki, Y. J. Gastroenterol. (2006) [Pubmed]
  29. The effects of sulphasalazine on urinary excretion of the hydroxypyridinium crosslinks of collagen in patients with rheumatoid arthritis. Dílek, K., Alí, I., Göksal, K., Hüseyin, T., Güner, T. Yonsei Med. J. (2002) [Pubmed]
  30. Expression of chemoresistance-related proteins in alpha-fetoprotein-producing adenocarcinoma of the digestive organs. Kamoshida, S., Suzuki, M., Sakurai, Y., Ochiai, M., Kimura, F., Kuwao, S., Sakamoto, K., Sugimoto, Y., Fukushima, M., Tsutsumi, Y. Oncol. Rep. (2006) [Pubmed]
  31. Regulation of genes of the circadian clock in human colon cancer: reduced period-1 and dihydropyrimidine dehydrogenase transcription correlates in high-grade tumors. Krugluger, W., Brandstaetter, A., Kállay, E., Schueller, J., Krexner, E., Kriwanek, S., Bonner, E., Cross, H.S. Cancer Res. (2007) [Pubmed]
  32. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Nishiyama, M., Yamamoto, W., Park, J.S., Okamoto, R., Hanaoka, H., Takano, H., Saito, N., Matsukawa, M., Shirasaka, T., Kurihara, M. Clin. Cancer Res. (1999) [Pubmed]
  33. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Hamdy, S.I., Hiratsuka, M., Narahara, K., El-Enany, M., Moursi, N., Ahmed, M.S., Mizugaki, M. British journal of clinical pharmacology. (2002) [Pubmed]
  34. Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Farrugia, D.C., Ford, H.E., Cunningham, D., Danenberg, K.D., Danenberg, P.V., Brabender, J., McVicar, A.D., Aherne, G.W., Hardcastle, A., McCarthy, K., Jackman, A.L. Clin. Cancer Res. (2003) [Pubmed]
  35. Dihydropyrimidine dehydrogenase activity and messenger RNA level may be related to the antitumor effect of 5-fluorouracil on human tumor xenografts in nude mice. Ishikawa, Y., Kubota, T., Otani, Y., Watanabe, M., Teramoto, T., Kumai, K., Kitajima, M., Takechi, T., Okabe, H., Fukushima, M. Clin. Cancer Res. (1999) [Pubmed]
  36. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma. Toriumi, F., Kubota, T., Saikawa, Y., Yoshida, M., Otani, Y., Watanabe, M., Kumai, K., Kitajima, M. Anticancer Res. (2004) [Pubmed]
 
WikiGenes - Universities